BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35131878)

  • 1. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53.
    Li J; Lama R; Galster SL; Inigo JR; Wu J; Chandra D; Chemler SR; Wang X
    Mol Cancer Ther; 2022 Apr; 21(4):535-545. PubMed ID: 35131878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
    Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
    PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.
    Li C; Yin X; Liu Z; Wang J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.
    Lama R; Xu C; Galster SL; Querol-García J; Portwood S; Mavis CK; Ruiz FM; Martin D; Wu J; Giorgi MC; Bargonetti J; Wang ES; Hernandez-Ilizaliturri FJ; Koudelka GB; Chemler SR; Muñoz IG; Wang X
    Front Oncol; 2022; 12():933446. PubMed ID: 35992795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell death in pancreatic cancer: from pathogenesis to therapy.
    Chen X; Zeh HJ; Kang R; Kroemer G; Tang D
    Nat Rev Gastroenterol Hepatol; 2021 Nov; 18(11):804-823. PubMed ID: 34331036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.
    McCubrey JA; Abrams SL; Steelman LS; Cocco L; Ratti S; Martelli AM; Lombardi P; Gizak A; Duda P
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
    McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
    Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
    Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
    Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
    Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
    J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.
    Godfrey JD; Morton JP; Wilczynska A; Sansom OJ; Bushell MD
    Cell Death Dis; 2018 May; 9(6):644. PubMed ID: 29844410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
    Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
    Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCC3 is a novel target for the treatment of pancreatic cancer.
    Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
    Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Yang C; Dong Q; Bao H; Ge Y; Xu Z; Li J; Jiang X; Xu Y; Zhong X
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):45. PubMed ID: 38287825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.
    Escobar-Hoyos LF; Penson A; Kannan R; Cho H; Pan CH; Singh RK; Apken LH; Hobbs GA; Luo R; Lecomte N; Babu S; Pan FC; Alonso-Curbelo D; Morris JP; Askan G; Grbovic-Huezo O; Ogrodowski P; Bermeo J; Saglimbeni J; Cruz CD; Ho YJ; Lawrence SA; Melchor JP; Goda GA; Bai K; Pastore A; Hogg SJ; Raghavan S; Bailey P; Chang DK; Biankin A; Shroyer KR; Wolpin BM; Aguirre AJ; Ventura A; Taylor B; Der CJ; Dominguez D; Kümmel D; Oeckinghaus A; Lowe SW; Bradley RK; Abdel-Wahab O; Leach SD
    Cancer Cell; 2020 Aug; 38(2):198-211.e8. PubMed ID: 32559497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.